Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models
暂无分享,去创建一个
Scott Boyer | M. Paul Gleeson | Andrew M. Davis | Kamaldeep K. Chohan | Stuart Paine | Claire L. Gavaghan | Catrin Hasselgren Arnby | Cecilia Kankkonen | Nan Albertson | C. H. Arnby | S. Boyer | A. Davis | M. Gleeson | C. Gavaghan | S. Paine | N. Albertson | Cecilia Kankkonen | K. Chohan
[1] J. Edward Jackson,et al. A User's Guide to Principal Components: Jackson/User's Guide to Principal Components , 2004 .
[2] F C Lightstone,et al. Quantitative structure‐activity relationship of flavonoids for inhibition of heterocyclic amine mutagenicity , 2000, Environmental and molecular mutagenesis.
[3] Pierre Bruneau,et al. Search for Predictive Generic Model of Aqueous Solubility Using Bayesian Neural Nets , 2001, J. Chem. Inf. Comput. Sci..
[4] H. Wold. Path Models with Latent Variables: The NIPALS Approach , 1975 .
[5] Eric F. Johnson,et al. The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution* , 2004, Journal of Biological Chemistry.
[6] S. O'Brien,et al. Greater than the sum of its parts: combining models for useful ADMET prediction. , 2005, Journal of medicinal chemistry.
[7] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[8] Maurice Dickins,et al. Compound lipophilicity for substrate binding to human P450s in drug metabolism. , 2004, Drug discovery today.
[9] Andrew G. Leach,et al. Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure. , 2006, Journal of medicinal chemistry.
[10] Dennis A. Smith,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .
[11] Leo Breiman,et al. Classification and Regression Trees , 1984 .
[12] C. Masimirembwa,et al. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. , 2001, Combinatorial chemistry & high throughput screening.
[13] Steven L. Dixon,et al. Use of Robust Classification Techniques for the Prediction of Human Cytochrome P450 2D6 Inhibition , 2003, J. Chem. Inf. Comput. Sci..
[14] Jose Cosme,et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.
[15] Han van de Waterbeemd,et al. Time‐Series QSAR Analysis of Human Plasma Protein Binding Data , 2007 .
[16] F Peter Guengerich,et al. Update Information on Human P450s , 2002, Drug metabolism reviews.
[17] Jeffrey P. Jones,et al. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[18] Jose Cosme,et al. Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.
[19] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[20] J. E. Jackson. A User's Guide to Principal Components , 1991 .
[21] Slobodan Petar Rendic,et al. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.
[22] M Paul Gleeson,et al. In silico human and rat Vss quantitative structure-activity relationship models. , 2006, Journal of medicinal chemistry.
[23] R J Riley,et al. Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[24] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[25] Anders Karlén,et al. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. , 2004, Journal of medicinal chemistry.
[26] Robert J Riley,et al. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. , 2003, British journal of clinical pharmacology.
[27] Glenn J. Myatt,et al. LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..
[28] N S Lewis,et al. The use of 'electronic nose' sensor responses to predict the inhibition activity of alcohols on the cytochrome P-450 catalyzed p-hydroxylation of aniline. , 2000, Bioorganic & medicinal chemistry.
[29] R. J. Riley,et al. Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.
[30] Frank E. Blaney,et al. Crystal Structure of Human Cytochrome P450 2D6* , 2005, Journal of Biological Chemistry.
[31] A. Y. Lu,et al. Inhibition and Induction of Cytochrome P450 and the Clinical Implications , 1998, Clinical pharmacokinetics.
[32] G. Schneider,et al. A Virtual Screening Filter for Identification of Cytochrome P450 2C9 (CYP2C9) Inhibitors , 2007 .
[33] M. Dickins,et al. Quantitative Structure-Activity Relationships (QSARs) Within Substrates of Human Cytochromes P450 Involved in Drug Metabolism , 2001, Drug metabolism and drug interactions.
[34] Bruce R. Kowalski,et al. Chemometrics, mathematics and statistics in chemistry , 1984 .
[35] Robert J Riley,et al. The influence of DMPK as an integrated partner in modern drug discovery. , 2002, Current drug metabolism.
[36] Scott Boyer,et al. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data , 2007, J. Comput. Aided Mol. Des..
[37] C. Hansch,et al. p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .
[38] J. Ruuskanen,et al. Performance of (consensus) kNN QSAR for predicting estrogenic activity in a large diverse set of organic compounds , 2004, SAR and QSAR in environmental research.
[39] I. Pajeva,et al. Quantitative structure-activity relationship (QSAR) and three-dimensional QSAR analysis of a series of xanthates as inhibitors and inactivators of cytochrome P450 2B1 , 2002, Xenobiotica; the fate of foreign compounds in biological systems.
[40] J. Platts,et al. Correlation and prediction of a large blood-brain distribution data set--an LFER study. , 2001, European journal of medicinal chemistry.
[41] David F. V. Lewis,et al. Structure–activity relationship for human cytochrome P450 substrates and inhibitors , 2002, Drug metabolism reviews.
[42] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[43] Jeffrey P. Jones,et al. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. , 2000, Journal of medicinal chemistry.
[44] Luc Morin-Allory,et al. 2D QSAR Consensus Prediction for High-Throughput Virtual Screening. An Application to COX-2 Inhibition Modeling and Screening of the NCI Database , 2004, J. Chem. Inf. Model..
[45] S. Wold,et al. Multi‐way principal components‐and PLS‐analysis , 1987 .
[46] M. Abraham,et al. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship. , 1999, Journal of pharmaceutical sciences.
[47] M Paul Gleeson,et al. Plasma protein binding affinity and its relationship to molecular structure: an in-silico analysis. , 2007, Journal of medicinal chemistry.
[48] A. Tropsha,et al. Beware of q2! , 2002, Journal of molecular graphics & modelling.
[49] Jaina Mistry,et al. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. , 2005, Journal of medicinal chemistry.
[50] D. Lewis,et al. Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. , 2004, Toxicology in vitro : an international journal published in association with BIBRA.